Technology | Advanced Visualization | May 11, 2018

EnvoyAI, TeraRecon and Insignia Bringing Artificial Intelligence to U.K. Customers

Integration brings AI-enhanced imaging workflows to Insignia’s InSight PACS and TeraRecon’s iNtuition advanced visualization software

EnvoyAI, TeraRecon and Insignia Bringing Artificial Intelligence to U.K. Customers

May 11, 2018 — EnvoyAI announced a new integration with Insignia Medical Systems’ InSight PACS (picture archiving and communication system) to provide artificial intelligence (AI)-enhanced imaging workflows to customers. For initial launch in the U.K., this integration provides curated AI content available on the EnvoyAI platform within the PACS environment at multiple integration points.  These include AI results viewing directly within the PACS viewer, as well as within the already established Insignia integration with TeraRecon.

The integrations with EnvoyAI and TeraRecon allow hospitals to customize their AI portfolio based on algorithms they can test and consume from within their Insignia PACS, including the utilization of each hospital’s own internally developed algorithms.

The EnvoyAI platform readies the Insignia InSight PACS for the launch of any AI application – starting with the AI content already available on the EnvoyAI Exchange.  With recent growth, the EnvoyAI Exchange now offers a total of 53 products from 22 partners, of which 10 have already achieved U.S. Food and Drug Administration (FDA) clearance. The partnership creates added potential for future workflow integrations to TeraRecon’s iNtuition advanced visualization solution already promoted by Insignia, as well as TeraRecon’s new NorthStar AI-results viewer for advanced physician interactions.

The integration will be displayed in the EnvoyAI and TeraRecon booths at the 2018 Society for Imaging Informatics in Medicine (SIIM) Annual Meeting, May 31-June 2 in National Harbor, Md.

For more information: www.terarecon.com, www.envoyai.com, www.insigniamedical.co.uk

 

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 07, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
A recent study earlier this year in the journal Nature, which included researchers from Google Health London, demonstrated that artificial intelligence (AI) technology outperformed radiologists in diagnosing breast cancer on mammograms
Feature | Breast Imaging | April 06, 2020 | By Samir Parikh
A recent study earlier this year in the journal Nature,
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 the company is now offering a suite of AI solutions Vuno Med-LungQuant and Vuno Med-Chest X-ray for COVID-19, encompassing both lung X-ray and computed tomography (CT) modalities respectively all at once
News | Artificial Intelligence | April 02, 2020
April 2, 2020 — In the face of the COVID-19 pand
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 The Chinese start-up company Infervision launches its AI-based solution InferRead CT Lung Covid-19 also in Europe
News | Artificial Intelligence | March 31, 2020
March 31, 2020 — Lung infections generated by the coronavirus can be detected in...